Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Financial Officer | December 09, 2025 | December 11, 2025 |
| Faeth Therapeutics, Inc.SNSE · Entity 5029 | Director | May 21, 2025 | May 23, 2025 |
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | CFO and CBO | February 08, 2023 | February 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date December 09, 2025 · Filed December 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.51 · Expires 2035-12-08 | Direct | 480,000 |
Reported balance
After 2025-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-09 · Grant · Acquired 480,000 · Balance 480,000 F1: 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Faeth Therapeutics, Inc.
Report date May 21, 2025 · Filed May 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.32 · Expires 2035-05-20 | Direct | 19,000 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Grant · Acquired 19,000 · Balance 19,000 F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.
Viridian Therapeutics, Inc.\DE
Report date February 08, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.20 · Expires 2033-02-08 | Direct | 108,000 |
Reported balance
After 2023-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-08 · Grant · Acquired 108,000 · Balance 108,000 F1: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foghorn Therapeutics Inc.
Report date November 14, 2025 · Filed November 17, 2025
Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2025 Filed Dec 11, 2025 16:18 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 480,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001193125-25-315989 · ownership.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2035-12-08 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest on the first anniversary measured from November 17, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| May 21, 2025 Filed May 23, 2025 20:30 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.32 | $0.00 |
DisclosureSEC source: 0001415889-25-014482 · form4-05232025_040506.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or May 21, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 16:15 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (right to buy) · Derivative | 120,000 | $4.37 Strike: $4.37 | $524,400.00 |
DisclosureSEC source: 0001562180-25-000505 · primarydocument.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-01-21 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on January 22, 2026, and thereafter at a rate of 6.25% of the underlying shares on the first day of each calendar quarter. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:06 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001415889-24-016693 · form4-06132024_090600.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-10 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 11, 2025, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| April 16, 2024 Filed Apr 17, 2024 16:01 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Option (Right to buy) · Derivative | 275,000 | $6.03 Strike: $6.03 | $1,658,250.00 |
DisclosureSEC source: 0001562180-24-003439 · primarydocument.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2034-04-15 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares of common stock on April 16, 2025, and at a rate of 6.25% of the underlying shares thereafter on the first day of each calendar quarter until the option is fully vested. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:50 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-042098 · doc4.xml · derivative · entry 2 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2033-07-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 20:50 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042098 · doc4.xml · nonDerivative · entry 1 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,932 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 16:49 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 108,000 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-23-004592 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0001209191-22-036667 · doc4.xml · derivative · entry 2 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 20:15 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantCommon Stock | 4,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036667 · doc4.xml · nonDerivative · entry 1 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,466 F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or June 10, 2023, subject to the Reporting Person's continuous service with the Issuer through such vesting date. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 18:15 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004673 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 16:16 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 121,371 | $0.00 Strike: $19.77 | $0.00 |
DisclosureSEC source: 0000899243-22-000130 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,371 Underlying: Common Stock · 121,371 shares Expires 2031-12-31 F1 · derivative.exercise_date: The option vests 25% on July 26, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| July 30, 2021 Filed Aug 2, 2021 20:20 UTC | Faeth Therapeutics, Inc. SNSE · Entity 5029 | GrantStock Option (Right to Buy) · Derivative | 16,667 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0000899243-21-030982 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2031-07-29 F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the shares underlying the option granted shall vest and become exercisable each month following July 30, 2021, over three years such that the options shall be 100% vested on July 30, 2024, subject to the grantee's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) through each such vesting date. Read SEC document |
| July 26, 2021 Filed Jul 27, 2021 17:02 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 360,000 | $0.00 Strike: $17.09 | $0.00 |
DisclosureSEC source: 0000899243-21-030131 · doc4.xml · derivative · entry 1 Humer Kristian · CIK 0001872280 · CFO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,000 Underlying: Common Stock · 360,000 shares Expires 2031-07-26 F1 · derivative.exercise_date: The option vests 25% on July 26, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.